Ambit Biosciences - Top 20 VC deals of 2007

Company: Ambit Biosciences
Based: San Diego-CA
Amount: $49M
Round: Forth
Investors: Aisling Capital, Avalon Ventures, Canadian Medical Discoveries Fund, F. Hoffmann - La Roche, Forward Ventures, GIMV, GeneChem Financial Corporation, MedImmune, OrbiMed Advisors, Radius Ventures, Undisclosed Investor, Undisclosed Venture Firm

Scoop: The funding is being used to support advancement of Ambit’s product pipeline, which includes several drug candidates in clinical and pre-clinical development. They included AC220 for Acute Myeloid Leukemia, a preclinical drug for colon, prostate, breast, lung, pancreatic and other cancers, and another drug for melanoma. Ambit was recently spotlighted in our weekly Emerging Drug Developer column. It was also a 2006 Fierce 15 company.

More News:
Emerging Drug Developer: Ambit Biosciences. Report
Ambit Biosciences garners $49M in Series D. Report

Ambit Biosciences - Top 20 VC deals of 2007

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

Durect’s share price fell 12% after half of the panel of painkiller experts recommended against approving Posimir.

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite.